implantable hemodynamic pulmonary artery pressure (pap) monitoring  (CardioMEMS Inc)

Journal: Journal of Clinical Medicine

Article Title: Heart Failure Management through Telehealth: Expanding Care and Connecting Hearts

doi: 10.3390/jcm13092592

Figure Lengend Snippet: A selection of the main inclusion and exclusion criteria applied in the most relevant trials studying invasive hemodynamic monitoring.

Article Snippet: CHAMPION [ ] , Prospective, multicenter, randomized, single-blind trial of 550 patients who received an implantable hemodynamic monitor (CardioMems) , During the entire follow-up (mean 15 months [SD 7]), the treatment group had a 37% reduction in HF-related hospitalization compared with the control group (158 vs. 254, HR 0.63, 95% CI 0.52–0.77; p < 0.0001). , HF patients (symptoms > 3 months) with NYHA functional class III HF regardless of LVEF. At least 1 hospitalization for HF in the last 12 months. In patients with reduced LVEF, a beta-blocker, ACE-I, or ARB should be administrated with stable dosage for at least 1 month. , Implantation of CRT less than 3 months before enrollment. Experienced a major cardiac event (e.g., AMI, stroke) within 2 months of screening visit. eGFR less than 25 mL/min or chronic renal dialysis. Likely to undergo HTx within 6 months of screening visit..

Techniques: Selection, Control, Functional Assay, Plasmid Preparation